Michal Bassani-Sternberg

List of Publications by Year
in descending order

63	5,589	101543	144013
papers	citations	36 h-index	57 g-index

78	78	78	5222
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nature Communications, 2016, 7, 13404.	12.8	613
2	Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation. Molecular and Cellular Proteomics, 2015, 14, 658-673.	3.8	445
3	Large-scale identification of leaf senescence-associated genes. Plant Journal, 2003, 36, 629-642.	5.7	340
4	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	28.9	287
5	Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Computational Biology, 2017, 13, e1005725.	3.2	250
6	High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonî³-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. Molecular and Cellular Proteomics, 2018, 17, 533-548.	3.8	224
7	Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology, 2019, 37, 1283-1286.	17.5	208
8	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications, 2020, 11, 1293.	12.8	196
9	Mass spectrometry-based antigen discovery for cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 9-17.	5.5	165
10	Predicting Antigen Presentationâ€"What Could We Learn From a Million Peptides?. Frontiers in Immunology, 2018, 9, 1716.	4.8	159
11	Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptideâ€"HLA Interactions. Journal of Immunology, 2016, 197, 2492-2499.	0.8	150
12	Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652.	46.4	148
13	The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands. Journal of Immunology, 2018, 201, 3705-3716.	0.8	145
14	â€˜Hotspotsâ€™ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. Frontiers in Immunology, 2017, 8, 1367.	4.8	133
15	Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18769-18776.	7.1	127
16	Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell, 2018, 175, 159-170.e16.	28.9	127
17	The SysteMHC Atlas project. Nucleic Acids Research, 2018, 46, D1237-D1247.	14.5	119
18	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112

#	Article	IF	Citations
19	Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*. Molecular and Cellular Proteomics, 2018, 17, 2347-2357.	3.8	105
20	The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome. Molecular and Cellular Proteomics, 2013, 12, 1853-1864.	3.8	99
21	T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells InÂVitro and inÂMice. Gastroenterology, 2015, 149, 1042-1052.	1.3	96
22	Identification of tumor antigens with immunopeptidomics. Nature Biotechnology, 2022, 40, 175-188.	17.5	93
23	A Case for a Human Immuno-Peptidome Project Consortium. Immunity, 2017, 47, 203-208.	14.3	84
24	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell Reports Medicine, 2021, 2, 100194.	6.5	77
25	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinomaâ€"A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	4.8	73
26	Differential expression profiles of growth-related genes in the elongation zone of maize primary roots. Plant Molecular Biology, 2004, 56, 367-380.	3.9	66
27	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 2021, 36, 109412.	6.4	60
28	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. Cancer Cell, 2020, 37, 674-689.e12.	16.8	55
29	The Human Immunopeptidome Project, a Suggestion for yet another Postgenome Next Big Thing. Molecular and Cellular Proteomics, 2011, 10, O111.011833.	3.8	53
30	Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction. Molecular and Cellular Proteomics, 2021, 20, 100080.	3.8	49
31	The C-terminal extension landscape of naturally presented HLA-I ligands. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5083-5088.	7.1	48
32	High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry. Methods in Molecular Biology, 2019, 1913, 67-79.	0.9	48
33	Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands. Molecular and Cellular Proteomics, 2020, 19, 390-404.	3.8	47
34	Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature, 2022, 603, 721-727.	27.8	47
35	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. Methods in Molecular Biology, 2018, 1719, 209-221.	0.9	46
36	Current tools for predicting cancer-specific T cell immunity. OncoImmunology, 2016, 5, e1177691.	4.6	45

#	Article	IF	Citations
37	Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British Journal of Cancer, 2019, 120, 424-434.	6.4	44
38	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	4.4	42
39	Mass spectrometryâ€"driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight, 2019, 4, .	5.0	42
40	Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nature Biotechnology, 2022, 40, 656-660.	17.5	41
41	Comment on â€œA subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligandsâ€. Science Immunology, 2019, 4, .	11.9	39
42	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	6.0	27
43	Minimal Information About an Immunoâ€Peptidomics Experiment (MIAIPE). Proteomics, 2018, 18, e1800110.	2.2	23
44	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Molecular and Cellular Proteomics, 2021, 20, 100032.	3.8	22
45	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature Communications, 2021, 12, 6423.	12.8	18
46	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
47	Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927.		14
48	Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates. Cancer Immunology Research, 2022, 10, 275-284.	3.4	14
49	Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines. Vaccines, 2020, 8, 271.	4.4	13
50	Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. Frontiers in Immunology, 2020, 11, 1981.	4.8	9
51	Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands. Frontiers in Immunology, 2019, 10, 2731.	4.8	8
52	Editorial: Novel Strategies for Anti-Tumor Vaccines. Frontiers in Immunology, 2019, 10, 3117.	4.8	7
53	A roadmap for driving CAR TÂcells toward the oncogenic immunopeptidome. Cancer Cell, 2022, 40, 20-22.	16.8	7
54	Subtractive Hybridization Techniques to Study Cellular Senescence. Methods in Molecular Biology, 2007, 371, 289-305.	0.9	6

#	Article	IF	Citations
55	Deciphering the landscape of phosphorylated HLA-II ligands. IScience, 2022, 25, 104215.	4.1	3
56	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. Cancers, 2021, 13, 5801.	3.7	2
57	Immune pressure sculps tumor cells and trims high-quality mutations. Cancer Cell, 2022, 40, 717-719.	16.8	1
58	1088 In-depth Analysis of Cancer HLA-I Peptidomes. European Journal of Cancer, 2012, 48, S262.	2.8	0
59	P32. High resolution mass spectrometry reveals the depth and diversity of HLA-I peptidomes. , 2014, 2, .		0
60	P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma. , 2014, 2, .		0
61	O98 T-CELL RE-DIRECTION AGAINST GLYPICAN-3 FOR IMMUNOTHERAPY OF HEPATOCELLULAR CARCINOMA (HCC). Journal of Hepatology, 2014, 60, S40.	3.7	0
62	ITOC2 â€“ 021. The melanoma immune-peptidome for T-cell-based anti-tumour immunotherapies. European Journal of Cancer, 2015, 51, S8.	2.8	0
63	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. Journal of Clinical Oncology, 2021, 39, 2533-2533.	1.6	0